GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » PensionAndRetirementBenefit

Akeso (HKSE:09926) PensionAndRetirementBenefit : HK$0 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Akeso PensionAndRetirementBenefit?

Akeso's PensionAndRetirementBenefit for the quarter that ended in Dec. 2023 was HK$0 Mil.


Akeso PensionAndRetirementBenefit Historical Data

The historical data trend for Akeso's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso PensionAndRetirementBenefit Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PensionAndRetirementBenefit
Get a 7-Day Free Trial - - - - -

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Akeso PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


Akeso (HKSE:09926) Business Description

Industry
Traded in Other Exchanges
Address
6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.
Executives
Xia Yu 2501 Other
Wang Zhongmin Maxwell 2501 Other
Li Baiyong 2501 Other
Green Court Capital Holdings Limited 2201 Interest of corporation controlled by you
Green Court Capital Management Limited 2102 Investment manager
Green Court Management Holdings Llc 2201 Interest of corporation controlled by you
Yao Yulin 2201 Interest of corporation controlled by you
Shenzhen Capital Group Co., Ltd. 2201 Interest of corporation controlled by you
Xia Yu 2501 Other
Shen Zhen Shi Chuang Xin Tou Zi Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Zheng Xun
Zhong Shan Shi Xun Xiang Gu Quan Tou Zi Guan Li Qi Ye You Xian He Huo
Cantrust (far East) Limited 2301 Trustee
Aquae Hyperion Limited 2101 Beneficial owner
Htkf Investments Limited 2101 Beneficial owner

Akeso (HKSE:09926) Headlines

No Headlines